Drug intelligence / Profile preview

k-selenocarrageenan

Development stage
Preclinical
Modality
Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration
Oral
01

Overview

**k-selenocarrageenan** is an organic selenium-modified polysaccharide derived from κ-carrageenan, in which selenium atoms partially replace the native sulfate groups. It retains the basic structure of κ-carrageenan, a marine red algae sulfated polysaccharide, but exhibits additional biological activity due to the presence of selenium. K-selenocarrageenan has been shown to possess immunomodulatory and anti-tumor effects in preclinical models, especially for inhibiting tumor growth and modulating inflammatory responses. Low molecular weight derivatives, such as κ-selenocarrageenan oligosaccharides, can be enzymatically produced and have improved bioavailability and enhanced activity compared to their parent polysaccharide. These oligosaccharides reduce colonic inflammation and modulate gut microbiota composition in animal models of ulcerative colitis, primarily by suppressing inflammatory cytokine signaling (tumor necrosis factor-α, interleukin-6, interleukin-10) and neutrophil infiltration. In cancer studies, k-selenocarrageenan exhibits cell cycle modulation, blocking cells in S phase and inhibiting key regulators like cyclin A, Cdk2, and Cdc25A.

Brand names
k-selenocarrageenan
Other names
κ-selenocarrageenanKSCseleno-kappacarrageenan
02

Targets

CDC25A (Cell division cycle 25A phosphatase)CCNA2 (Cyclin A2)CDK2 (Cyclin-dependent kinase 2)IL10 (Interleukin-10)IL-6 (Interleukin 6)TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on k-selenocarrageenan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on k-selenocarrageenan.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call